Issue 5/2012

  • It's finally spring for EU biotechs

    In this issue:

    • Austrian efforts to implement a total national ban on GMOs
    • Finland's UPM invests €150m in biodiesel refinery
    • AstraZeneca to take over US gout drug specialist Ardea
    • SPECIAL: Contract Research – Opportunities for outsourcing
    • Cancer start-up Vivia Biotech secures Series B financing 
    • Gedeon Richter opens huge biologics manufacturing plant
    • Databases link cancer cell genomics to drug efficacy

Volume 2016

Volume 2015

Volume 2014

Volume 2013

Volume 2012

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/5/pos/1.html?cHash=2aa63e7a3c47f54d547eeaaa494e591b&sort=asc

Kurszettel

Alle Kurse

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • THERAMETRICS (CH)0.03 CHF50.00%
  • PLETHORA (UK)3.38 GBP12.67%

FLOP

  • OXFORD BIOMEDICA (UK)5.52 GBP-8.76%
  • IXICO (UK)39.00 GBP-4.88%
  • BIONOR PHARMA (N)0.85 NOK-4.49%

TOP

  • AB SCIENCE (F)19.21 EUR71.5%
  • SYNAIRGEN (UK)36.25 GBP48.0%
  • BIOFRONTERA (D)3.14 EUR38.3%

FLOP

  • EVOLVA (CH)0.68 CHF-26.1%
  • SERODUS (N)1.70 NOK-26.1%
  • THERAMETRICS (CH)0.03 CHF-25.0%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)31.40 SEK2065.5%
  • NICOX (F)8.73 EUR352.3%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.00 SEK-88.2%
  • BB BIOTECH (D)47.86 EUR-81.9%
  • BIOTEST (D)17.00 EUR-77.0%

No liability assumed, Date: 28.04.2016